To the full analysis
Buyback calculator for Ascendis Pharma
Ascendis Pharma stock: key metrics
ASNDAscendis Pharma had an operating margin of −18.9% and a return on invested capital (ROIC) of −72.8% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2012 | 100.0% | 9.7% | 8.0% |
| 2013 | 100.0% | 25.9% | 20.0% |
| 2014 | 100.0% | −85.7% | −69.1% |
| 2015 | 100.0% | −515.2% | −405.5% |
| 2016 | 100.0% | −1,583.2% | −1,487.3% |
| 2017 | 100.0% | −7,290.3% | −8,097.8% |
| 2018 | 100.0% | −1,462.6% | −1,229.5% |
| 2019 | 100.0% | −1,695.1% | −1,630.0% |
| 2020 | 100.0% | −4,755.1% | −6,025.5% |
| 2021 | 54.7% | −5,808.6% | −4,931.6% |
| 2022 | 76.3% | −1,097.9% | −1,139.6% |
| 2023 | 83.4% | −170.8% | −180.5% |
| 2024 | 87.8% | −76.7% | −104.0% |
| 2025 | 85.1% | −18.9% | −31.7% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2012 | 80.3% | 147.0% | 4.9% |
| 2013 | 64.7% | 116.5% | 15.3% |
| 2014 | −21.1% | −36.4% | −16.5% |
| 2015 | −27.4% | −39.8% | −25.0% |
| 2016 | −38.8% | −38.8% | −36.0% |
| 2017 | −66.2% | −48.4% | −58.7% |
| 2018 | −46.5% | −52.3% | −40.8% |
| 2019 | −36.5% | −39.4% | −32.2% |
| 2020 | −50.0% | −33.6% | −42.8% |
| 2021 | −43.4% | −37.2% | −35.4% |
| 2022 | −100.0% | −49.9% | −53.5% |
| 2023 | 200.0% | −55.5% | −58.3% |
| 2024 | 200.0% | −34.6% | −32.1% |
| 2025 | 134.6% | −72.8% | −16.8% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Fairly valued since 7 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.